As­traZeneca push­es for­ward with Tagris­so com­bos, tout­ing PhII da­ta with Hutchmed drug

In a new da­ta read­out ex­plor­ing a po­ten­tial Tagris­so com­bi­na­tion ther­a­py, As­traZeneca re­vealed Mon­day morn­ing that it’s all about the MET.

As­traZeneca re­port­ed that 32% of about 200 lung can­cer pa­tients tak­ing a com­bo of Tagris­so and savoli­tinib, co-de­vel­oped with Hutchmed, re­spond­ed to the ther­a­py in a sin­gle-arm, Phase II tri­al. But that re­sponse rate jumped to 49% in pa­tients with high lev­els of the MET bio­mark­er, in­di­cat­ing a pos­si­bly promis­ing path for­ward for the Big Phar­ma’s emerg­ing block­buster — and it’s here where As­traZeneca is fo­cus­ing the spot­light.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER